HOOKIPA Pharma Inc. (HOOK) |
|
0.6011 -0.024 (-3.82%)
|
09-28 16:00 |
|
Open: |
0.63 |
Pre. Close: |
0.625 |
|
High:
|
0.63 |
Low:
|
0.6 |
|
Volume:
|
149,298 |
Market Cap:
|
50(M) |
|
|
|
Technical analysis |
as of: 2023-09-28 4:51:06 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 0.79 One year: 0.88 |
| Support: |
Support1: 0.55 Support2: 0.45 |
| Resistance: |
Resistance1: 0.67 Resistance2: 0.75 |
| Pivot: |
0.64 |
| Moving Average: |
MA(5): 0.6 MA(20): 0.65
MA(100): 0.92 MA(250): 0.95 |
| MACD: |
MACD(12,26): -0.1  Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 27.5 %D(3): 22 |
| RSI: |
RSI(14): 37.4 |
| 52-week: |
High: 2.04 Low: 0.55 |
| Average Vol(K): |
3-Month: 460 (K) 10-Days: 442 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ HOOK ] has closed above bottom band by 26.2%. Bollinger Bands are 58.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 56 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.63 - 0.63 |
0.63 - 0.64 |
|
Low:
|
0.59 - 0.6 |
0.6 - 0.6 |
|
Close:
|
0.6 - 0.6 |
0.6 - 0.61 |
|
Company Description |
|
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York. |
Headline News |
Thu, 28 Sep 2023
RBC Capital Reiterates Hookipa Pharma (HOOK) Outperform ... - Nasdaq
Wed, 27 Sep 2023
The Importance of Research Funding for the Thriving Medical ... - Best Stocks
Wed, 27 Sep 2023
Intriguing OffMarket Block Trade Indicates Sellers Urgency to Sell ... - Best Stocks
Wed, 13 Sep 2023
HOOKIPA Announces Executive Leadership Change - GlobeNewswire
Wed, 06 Sep 2023
7 Biotech Stocks to Sell in September Before They Crash & Burn - InvestorPlace
Wed, 06 Sep 2023
HOOKIPA Pharma to participate in upcoming investor conferences ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
82 (M) |
| Shares Float |
57 (M) |
|
% Held by Insiders
|
5 (%) |
|
% Held by Institutions
|
40.5 (%) |
|
Shares Short
|
225 (K) |
|
Shares Short P.Month
|
288 (K) |
Stock Financials |
|
EPS
|
-0.88 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.34 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-494.7 |
|
Return on Assets (ttm)
|
-27.1 |
|
Return on Equity (ttm)
|
-56 |
|
Qtrly Rev. Growth
|
-2.5 |
|
Gross Profit (p.s.)
|
-0.65 |
|
Sales Per Share
|
0.19 |
|
EBITDA (p.s.)
|
-0.93 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-26 (M) |
|
Levered Free Cash Flow
|
-27 (M) |
Stock Valuations |
|
PE Ratio
|
-0.69 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0.44 |
|
Price to Sales
|
3.08 |
|
Price to Cash Flow
|
-1.92 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
